Experts from InSilico Medicine and its partners successfully established a visual mapping of the molecular pathway cancer progression originating from myeloid derived suppressor cells (MDSC).
Development of New Cancer Drugs Possible With Gene Mutation
Drugs that block the rapid, unstoppable cell division in cancer that makes it so deadly, could now be possible with the discovery of a gene mutation that causes a rare premature aging disease.
Drugs that block the rapid, unstoppable cell division in cancer that makes it so deadly, could now be possible with the discovery of a gene mutation that causes a rare premature aging disease.
But the key transcriptional regulators of MDSC are still poorly defined. Alex and colleagues used bioinformatic tools to investigate the pathway interactome maps in colon and breast cancer models. Several proliferation and invasion-related pathways were identified in infiltrating MDSC. It opens a door to new therapy targeting MDSC in these diseases. " says Qingsong Zhu, COO of InSilico Medicine, Inc.
Source-Eurekalert
Early Cancer Detection Could Be Done With A Blood Test
Lymphocyte Genome Sensitivity(LGS) test, is the newest blood test test developed by researchers to detect cancer in its early stages.
Lymphocyte Genome Sensitivity(LGS) test, is the newest blood test test developed by researchers to detect cancer in its early stages.
New Approach Accelerates Identification of Cancer Treatments
At the University of Michigan, researchers have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.
At the University of Michigan, researchers have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.
Standard Care for HER2-Positive Breast Cancer: Trastuzumab
Trastuzumab, Herceptin, should remain the standard of care for HER2-positive breast cancer, says a Mayo Clinic researcher, after analysis of more than 8,000 women with the cancer.
Trastuzumab, Herceptin, should remain the standard of care for HER2-positive breast cancer, says a Mayo Clinic researcher, after analysis of more than 8,000 women with the cancer.
